Charlotte’s Web: Did You Know?

For centuries, cannabis cultivators in various cultures have selectively bred plants for traits like potency and resin production. However, the late 20th century witnessed a surge in intentional breeding efforts by cannabis enthusiasts and researchers. Their goal: emphasising specific desirable traits, particularly cannabinoid profiles and therapeutic effects.

One pivotal moment arrived in 2011 with the creation of Charlotte's Web. Named after Charlotte Figi, a young girl suffering from severe epilepsy, this strain was meticulously bred to be high in cannabidiol (CBD) and low in tetrahydrocannabinol (THC). Charlotte's Web gained global attention for its remarkable success in reducing Charlotte's seizures, shining a spotlight on the potential of specific cannabis strains for addressing health conditions. 

By age three, Charlotte, despite conventional treatments, endured 300 seizures weekly. However, after using this specially formulated cannabis oil strain her epilepsy improved. In 2013, two years after starting treatment, Charlotte's seizure frequency fell from around 50 convulsive seizures per day to just 2-3 nocturnal convulsions per month.

Since then, a multitude of strains with varying ratios of cannabinoids have been developed to address specific medical conditions, such as chronic pain, anxiety, and nausea. Cultiva’s ongoing dedication to innovative genetics and developing new strains helps expand the plant's therapeutic potential and sets us apart as leaders in patient care.